# A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants

> **NCT01933880** · PHASE4 · COMPLETED · sponsor: **Xian-Janssen Pharmaceutical Ltd.** · enrollment: 194 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder (ADHD)

## Interventions

- **DRUG:** Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH)
- **OTHER:** No intervention

## Key facts

- **NCT ID:** NCT01933880
- **Lead sponsor:** Xian-Janssen Pharmaceutical Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 194 (ACTUAL)
- **Last updated:** 2014-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01933880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01933880, "A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01933880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*